🇺🇸 FDA
Pipeline program

Xofigo 1100 kBq/mL solution for injection

c16-174

Phase 3 small_molecule active

Quick answer

Xofigo 1100 kBq/mL solution for injection for metastatic Castration-Resistant Prostate Cancer (mCRPC) is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials